Comparison of Plasmin With Recombinant Tissue-Type Plasminogen Activator in Lysis of Cerebral Thromboemboli Retrieved From Patients With Acute Ischemic Stroke
Author(s) -
Victor J. Marder,
Aleš Blinc,
Theresa Gruber,
Gregor Tratar,
Mišo Šabovič,
Sidney Starkman,
Reza Jahan,
Gary Duckwiler,
Fernando Viñuela,
Satoshi Tateshima,
David S. Liebeskind,
Bruce Ovbiagele,
Letisha Ali,
Doojin Kim,
Nestor R. Gonzalez,
Paul Vespa,
Jeffrey L. Saver
Publication year - 2011
Publication title -
stroke
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.397
H-Index - 319
eISSN - 1524-4628
pISSN - 0039-2499
DOI - 10.1161/strokeaha.110.609198
Subject(s) - medicine , thrombolysis , plasmin , ex vivo , thrombus , stroke (engine) , plasminogen activator , tissue plasminogen activator , streptokinase , in vivo , fibrinolysis , fibrinolytic agent , d dimer , t plasminogen activator , cardiology , anesthesia , biochemistry , myocardial infarction , biology , enzyme , mechanical engineering , microbiology and biotechnology , engineering
Plasmin is a direct-acting thrombolytic with a better safety profile than recombinant tissue-type plasminogen activator (rtPA) in animal models. With the application of retrieval devices for managing acute ischemic stroke, extracted thromboemboli are available for ex vivo examination. We ask whether such thrombi are amenable to plasmin thrombolysis and whether such activity is different with rtPA.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom